Inpharma 1605 - 15 Sep 2007 Antihyperlipidaemics demonstrate long-term survival benefits Long-term follow-up data from the PRIME study showed reductions in all-cause mortality with lipid- lowering medications. This prospective study involved 7855 men aged 50–60 years old who either received statin (HMG-CoA reductase inhibitor; n = 310) or fibric acid derivative (fibrates; 809) therapy, or received no such therapy and were normolipidaemic (5340) or dyslipidaemic; * participants were followed up for 10 years. Cox proportional hazards modelling showed that, compared with participants with untreated dyslipidaemia, participants who received statins or fibric acid derivatives had a significantly reduced all- cause mortality risk (HR 0.49; 95% CI 0.25, 0.93 and 0.65; 0.43, 0.99, respectively) and a reduced cardiovascular mortality risk (0.46; 0.13, 1.54 and 0.65; 0.31, 1.36). Corresponding values for untreated normolipidaemic patients were 0.76; 0.56, 1.02 and 0.38; 0.21, 0.61, respectively. Moreover, cancer mortality risk was also decreased among statin and fibric acid derivative recipients, and untreated normolipidaemic participants, compared with untreated dyslipidaemic participants (0.39; 0.15, 1.01, 0.51; 0.27, 0.96 and 0.70; 0.45, 1.07). There were no significant differences between groups in terms of mortality due to other causes. * defined as having a total cholesterol level of ≥ 250 mg/dL or a triglyceride level of ≥ 300 mg/dL Gardette V, et al. Ten year all-cause mortality on lipid-lowering drugs ESC Congress 2007: Annual Congress of the European Society of Cardiology : 1 Sep 2007 801035823 1 Inpharma 15 Sep 2007 No. 1605 1173-8324/10/1605-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Antihyperlipidaemics demonstrate long-term survival benefits

Download PDF Report

View
212
Download
0

Embed Size (px)

Citation preview

Inpharma 1605 - 15 Sep 2007

Antihyperlipidaemics demonstratelong-term survival benefits

Long-term follow-up data from the PRIME studyshowed reductions in all-cause mortality with lipid-lowering medications.

This prospective study involved 7855 men aged50–60 years old who either received statin (HMG-CoAreductase inhibitor; n = 310) or fibric acid derivative(fibrates; 809) therapy, or received no such therapy andwere normolipidaemic (5340) or dyslipidaemic;*participants were followed up for 10 years.

Cox proportional hazards modelling showed that,compared with participants with untreateddyslipidaemia, participants who received statins orfibric acid derivatives had a significantly reduced all-cause mortality risk (HR 0.49; 95% CI 0.25, 0.93 and0.65; 0.43, 0.99, respectively) and a reducedcardiovascular mortality risk (0.46; 0.13, 1.54 and 0.65;0.31, 1.36). Corresponding values for untreatednormolipidaemic patients were 0.76; 0.56, 1.02 and0.38; 0.21, 0.61, respectively.

Moreover, cancer mortality risk was also decreasedamong statin and fibric acid derivative recipients, anduntreated normolipidaemic participants, compared withuntreated dyslipidaemic participants (0.39; 0.15, 1.01,0.51; 0.27, 0.96 and 0.70; 0.45, 1.07).

There were no significant differences between groupsin terms of mortality due to other causes.* defined as having a total cholesterol level of ≥ 250 mg/dL or atriglyceride level of ≥ 300 mg/dL

Gardette V, et al. Ten year all-cause mortality on lipid-lowering drugs ESCCongress 2007: Annual Congress of the European Society of Cardiology : 1 Sep2007 801035823